

## Special Issue

# Osteosarcoma: Individualized Precision Treatment and Effective Drug Discovery

### Message from the Guest Editor

This Special Issue seeks to explore the latest advancements and future directions in understanding the molecular mechanisms underlying bone and soft tissue sarcomas. By delving into the molecular landscape of these tumors, we aim to highlight novel therapeutic strategies and their potential to transform the treatment of these challenging diseases. Recent years have witnessed remarkable progress in targeted therapies and drug discovery for osteosarcoma. Advances in the molecular characterization of the disease have unveiled promising new targets and treatment avenues. In this Special Issue, we bring together cutting-edge research and insights to summarize recent breakthroughs in precision medicine and innovative drug discovery for osteosarcoma, offering hope for improved patient outcomes and a brighter future in the fight against this formidable malignancy.

---

### Guest Editor

Dr. Margherita Cortini

Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy

---

### Deadline for manuscript submissions

closed (28 February 2026)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/229133](https://mdpi.com/si/229133)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)